NCT06291948View on ClinicalTrials.gov

A Clinical Study With Adalimumab Biosimilar

PHASE1CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

January 10, 2023

Study Completion Date

October 20, 2023

Conditions

PharmacokineticsSafety Issues

Interventions

BIOLOGICAL

Humira® (adalimumab) AC Pen [Reference Product]

A single subcutaneous dose

BIOLOGICAL

Adalimumab Richmond [Test Product]

A single subcutaneous dose

Trial Locations (1)

C1425BAA

FP Clinical Pharma S.R.L., Buenos Aires

Sponsors

Collaborators (1)

Custom Biologics

All Listed Sponsors

collaborator

FP Clinical Pharma S.R.L.

INDUSTRY

collaborator

Custom Biologics

UNKNOWN

lead

Laboratorios Richmond S.A.C.I.F.

INDUSTRY